Page last updated: 2024-09-03

gefitinib and Breast Neoplasms

gefitinib has been researched along with Breast Neoplasms in 229 studies

Research

Studies (229)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	128 (55.90)	29.6817
2010's	86 (37.55)	24.3611
2020's	15 (6.55)	2.80

Authors

Authors	Studies
Jean-Claude, BJ; Macphee, M; Rachid, Z; Todorova, M; Williams, C	1
Jung, YS; Kim, YJ; Kwak, JH; Pyo, JS	1
Chen, Y; Kong, L; Li, C; Li, S; Lin, JY; Liu, M; Luo, J; Sun, H; Xia, Y; Yang, L; Yu, K; Yu, W; Zhang, W	1
Abadi, AH; Darwish, SS; Engel, M; Hamed, MM; Herrmann, J	1
Bao, CN; Li, ED; Li, N; Lin, Q; Liu, HM; Meng, YQ; Song, PP; Wang, JK; Xin, JC; Yang, P; Zhang, DQ; Zhang, LY; Zhang, QR; Zhang, Y	1
Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM	1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF	1
Aronis, C; Chaniotis, D; Degn, SE; Frantzi, T; Kalofonos, HP; Koutras, A; Makatsoris, T; Papanastasiou, AD; Sirinian, C	1
Liang, YJ	1
Abdelmalek, CM; Gehringer, M; Hesse, SS; Hu, Z; Kinnen, FJM; Kronenberger, T; Küblbeck, J; Kudolo, M; Laufer, SA; Malik, A; Niess, R; Witt-Enderby, PA; Zender, L; Zlotos, DP	1
Karki, N; Pal, M; Pandey, N; Rana, A; Rana, S; Sahoo, NG; Tewari, C; Tiwari, H	1
Acconcia, F	1
Alqahtani, AS; Harisa, GI; Nasr, FA; Shahba, AA; Sherif, AY; Taha, EI	1
He, J; Lin, C; Song, L; Tong, X	1
Aggarwal, G; Ahsan, W; Javed, S; Kumar, P; Mangla, B	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Baltes, F; Bendas, G; Caspers, J; Henze, S; Schlesinger, M	1
Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W	1
Chen, X; Tian, T; Ye, J	1
Aghanejad, A; Hamidi, AA; Nabi, PN; Omidi, Y; Tohidkia, MR; Vahidfar, N	1
Borrero-García, LD; Del Mar Maldonado, M; Dharmawardhane, S; Grafals-Ruiz, N; Medina-Velázquez, J; Troche-Torres, AL; Velazquez, L	1
Chen, YW; Chiou, SP; Chou, TL; Ho, MY; Li, LT; Liang, YJ; Lin, CY; Lin, YJ; Wang, CY; Wang, IA; Wang, YH; Yu, J	1
Li, Y; Liu, D; Quan, Y; Wu, B; Wu, Y; Zhang, D; Zhang, X	1
Fu, J; Hong, T; Huang, J; Ji, Q; Jin, S; Li, L; Li, Y; Liang, Y; Liu, Y; Lyu, Z; Song, Q; Wang, T; Xu, X; Ye, Q; You, W; Zhao, W	1
Amadori, D; Bongiovanni, A; De Vita, A; Ghetti, M; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Miserocchi, G; Recine, F; Spadazzi, C	1
Fang, D; Hou, JZ; Li, Q; Li, W; Ma, C; Niu, J; Sun, H; Wang, CJ; Xi, ZQ; Xie, SQ	1
An, YJ; Choi, SY; Im, JH; Jeong, BH; Kang, KW; Kim, SY; Kim, YG; Lee, JS; Park, S	1
Fang, D; Li, HY; Liang, C; Liu, FY; Niu, J; Sun, H; Wang, X; Xie, SQ; Zhang, YD	1
Díaz, L; García-Becerra, R; García-Quiroz, J; González-González, ME; Larrea, F; Ordaz-Rosado, D; Prado-García, H; Segovia-Mendoza, M	1
Bae, I; Hong, W; Kang, HJ; Kim, HJ; Seong, YS; Wang, A; Yi, YW; Zhao, W	1
Anandappa, G; Turner, NC	1
Bally, MB; Donohue, E; Dragowska, WH; Gelmon, KA; Gorski, SM; Kapanen, AI; Qadir, MA; Rawji, JS; Roberge, M; Wang, JC; Warburton, C; Weppler, SA; Wong, LY	1
Mehta, A; Tripathy, D	1
Bobilev, D; Peleg, R; Priel, E	1
Agelaki, S; Georgoulias, V; Kallergi, G; Kalykaki, A; Mavroudis, D; Xyrafas, A	1
Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T	1
Eroles, P; Lluch, A; Perez-Fidalgo, JA	1
Eisenstein, M	1
Dowsett, M; Gao, Q; Garcia-Murillas, I; López-Knowles, E; Martin, LA; Segal, CV; Smith, I; Turner, NC	1
Apte, RN; Kogan-Zviagin, I; Peleg, R; Priel, E; Romzova, M	1
Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; González-González, ME; Ibarra-Sánchez, MJ; Larrea, F; Martínez-Reza, I; Prado-Garcia, H; Segovia-Mendoza, M	1
Guan, X; Liu, Q; Wang, L; Wang, X; Xie, L; Yu, Z	1
Dong, W; Fang, S; Li, C; Li, M; Liu, J; Song, B; Tang, B; Wang, Z; Zhang, B; Zhang, X; Zhang, Y	1
Chang, JC; Colon-Otero, G; Dave, B; Patel, TA; Perez, EA; Rodriguez, AA	1
Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP	1
Al-Ejeh, F; Bessette, DC; Chenevix-Trench, G; Cocciardi, S; Grimmond, SM; Khanna, KK; Lakhani, SR; McCart-Reed, A; Quinn, MC; Saunus, JM; Seidens, T; Shi, W; Simpson, PT; Tilch, E; Waddell, N; Wiegmans, AP	1
Denny, EC; Kane, SE	1
Geng, D; Sun, D; Zhang, L; Zhang, W	1
Liu, W; Qin, ZP; Xing, RC; Yao, RC; Zheng, J; Zheng, WH	1
Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ	1
Ashinuma, H; Sekine, I	1
Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H	1
Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D	1
Watanabe, A	1
Luo, Z; Nitin, N; Samadzadeh, KM	1
Buiting, HM; de Kanter, W; Linn, SC; Smorenburg, CH	1
Cao, XJ; Garcia, BA; Kharbanda, A; Runkle, KB; Stypulkowski, E; Wang, W; Witze, ES	1
Chen, Y; Dendy, M; Gruvberger-Saal, SK; Hibshoosh, H; Horlings, HM; Isola, J; Jumppanen, M; Lau, YK; Maurer, M; Memeo, L; Parsons, R; Rosen, N; Saal, LH; She, QB; Su, T; van de Vijver, MJ	1
Allison, JP; Cha, JH; Chan, LC; Chang, SS; Ding, Q; Hortobagyi, GN; Hsu, JL; Hsu, JM; Hung, MC; Khoo, KH; Kim, T; Kuo, CW; Lee, CC; Lee, HH; Li, CW; Lim, SO; Sahin, AA; Wang, Y; Wu, HJ; Wu, Y; Xia, W; Yamaguchi, H; Yao, J; Yu, D	1
Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL	1
Neckers, L; Pashtan, I; Tsutsumi, S; Wang, S; Xu, W	1
Creighton, CJ; Hilsenbeck, SG; Huang, S; Malorni, L; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Tsimelzon, A	1
Arteaga, CL; Davidson, NE; Moulder, SL; O'Neill, A; Pins, M; Sledge, GW; Sparano, JA	1
Brunet, J; Del Barco, S; López-Bonet, E; Martín-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A	1
Clynes, M; Corkery, B; Crown, J; O'Donovan, N	1
Dai, J; Guo, D; Ji, C; Ma, D; Qu, X; Ye, J; Zang, S	1
Coombes, RC; Francis, RE; Guest, SK; Krol, J; Kwok, JM; Lam, EW; McGovern, UB; Myatt, SS; Peck, B; Polychronis, A; Wang, J	1
Casalini, P; Croce, CM; Di Leva, G; Iorio, MV; Ménard, S; Merlo, A; Piovan, C; Tagliabue, E; Triulzi, T	1
Burstein, HJ; Gelman, RS; Harris, LN; Mayer, EL; Partridge, AH; Schumer, ST; Winer, EP	1
Aliu, SO; Hann, BC; Hylton, NM; Li, KL; Moasser, MM; Wang, D; Wilmes, LJ	1
Agelaki, S; Georgoulias, V; Kallergi, G; Markomanolaki, H; Mavroudis, D; Spiliotaki, M; Stournaras, C	1
Basser, R; Chan, A; Fong, A; Forbes, JF; Francis, PA; Gebski, V; Green, MD; Harvey, V; Karapetis, C; Snyder, R	1
Fleisher, M; Hu, G; Kang, Y; Lu, X; Massagué, J; Reiss, M; Van Poznak, C; Wang, Q	1
Agrawal, A; Cheung, KL; Gee, J; Gutteridge, E; Nicholson, R; Robertson, J	1
Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY	1
Lee, CH	1
Choi, YH; Heo, MS; Kim, GY; Kim, MO; Lee, JD; Moon, DO	1
Wong, ST	1
D'Alessio, A; De Luca, A; Gallo, M; Lamura, L; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM	1
Gutteridge, E; Robertson, JF	1
Ali-Osman, F; Cao, X; Keir, S; Lo, HW; Zhu, H	1
Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C	1
Byrne, AT; Crown, J; Gallagher, WM; McGee, S; O'Connor, AE; O'Donovan, N	1
Cheng, Y; Hait, WN; Li, H; Niu, T; Ren, X; Yang, J	1
Harris, TJ; McCormick, F	1
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W	1
Atkinson, T; Berlin, ST; Bunnell, CA; Campos, SM; Chen, WY; Harris, L; Hirsch, MS; Krasner, CN; Lee, J; Matulonis, U; Parker, LM	1
Wörmann, B	1
Dong, Y; Li, A; Michel, LS; Wang, J; Weber, JD	1
Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A	1
Dennison, G; Foulstone, EJ; Frankow, A; Holly, JM; Jarrett, C; McIntosh, J; Perks, CM; Winters, ZE	1
Brunner, C; Hubalek, M; Marth, C; Matthä, K	1
Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V	1
Anagnostou, VK; Dirix, LY; Gutierrez, C; Mackey, JR; Magill, P; Migliaccio, I; Neven, P; Osborne, CK; Rimm, DL; Robert, J; Schiff, R; Sellers, M; Underhill, C	1
Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK	1
Chang, WC; Chen, AJ; Chen, CH; Chen, YJ; Chiu, PC; Hsu, SC; Huang, WC; Huang, WP; Hung, MC; Li, LY; Tsai, CH; Tsai, SL; Wang, YN; Wei, YL	1
Balslev, E; Bernsdorf, M; Ejlertsen, B; Grabau, D; Harder, E; Jakobsen, EH; Kroman, N; Lykkesfeldt, AE; von der Maase, H	1
Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL	1
Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H	1
Pandiella, A; Sánchez-Martín, M	1
Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z	1
Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA	1
Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B	1
Baker, JH; Bally, MB; Dragowska, WH; Franssen, Y; Gelmon, KA; Kapanen, AI; Kierkels, GJ; Masin, D; Minchinton, AI; Qadir, MA; Weppler, SA; Wong, LY	1
Bignon, YJ; Cayre, A; El Guerrab, A; Nemlin, CC; Penault-Llorca, F; Rossignol, F; Vigier, F; Zegrour, R	1
Chung, C; Frankel, P; Gu, L; Hurria, A; Kane, SE; Koczywas, M; Lau, SK; Leong, L; Luu, T; Martel, CL; McNamara, M; Morgan, R; Ruel, C; Russell, CA; Somlo, G	1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M	1
Dwivedi, A; Saxena, R	1
Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T	1
Eastman, BM; Gonias, SL; Jo, M; Takimoto, S; Webb, DL	1
Boerner, JL; Bollig-Fischer, A; Giordano, CR; Krentz, KA; Mueller, KL; Terlecky, LJ; Terlecky, SR	1
Cao, WF; Cao, XC; Feng, WH; Li, Y; Song, YQ; Zhang, B; Zhang, F; Zhang, L; Zhao, HM	1
Dutkowski, C; Farrow, L; Fiegl, H; Gee, JM; McClelland, RA; McCloy, RA; Musgrove, EA; Nicholson, RI; Stone, A; Sutherland, RL; Valdés-Mora, F	1
Bissell, MJ; Furuta, S; Kenny, PA; Lee, SY; Lenburg, ME; Meier, R; Xu, R	1
Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L	1
Castillo-Pichardo, L; Dharmawardhane, SF	1
Baxter, RC; Lin, MZ; Martin, JL; Marzec, KA	1
Guirgis, HM	1
Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A	1
Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S	1
Fischer, DC; Gabriel, B; Kieback, DG	1
Arteaga, CL; Moulder, SL; Yakes, FM	1
Ranson, M	1
Morris, C	1
Hynes, NE; Motoyama, AB	1
Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Tortora, G; Troiani, T; Veneziani, BM; Zangemeister-Wittke, U	1
Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; Madden, T; Nicholson, RI; Wakeling, AE	1
Schiller, JH	1
Albanell, J; Anido, J; Arribas, J; Averbuch, S; Baselga, J; Guzmán, M; Matar, P; Rojo, F	1
Arteaga, CL; Moulder, SL	1
Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE	1
Barrow, D; Gee, JM; Hutcheson, I; Knowlden, J; Madden, TA; McClelland, R; Nicholson, RI	1
Basso, A; Moasser, MM; She, QB; Solit, D	1
Campiglio, M; Fumagalli, M; Gianni, L; Locatelli, A; Ménard, S; Normanno, N; Olgiati, C; Somenzi, G; Viganò, L	1
Calvo, F; Ma, L; Menashi, S; Mourah, S; Serova, M; Vignot, S	1
Basso, A; Chung, EJ; Jung, YJ; Neckers, L; Rosen, N; Trepel, J; Xu, W; Yang, Y; Yuan, X	1
Konecny, GE; Slamon, DJ; Wilson, CA	1
Brown, PH; Celestino, J; Hill, J; Hilsenbeck, S; Kim, H; Lu, C; Mohsin, SK; Osborne, CK; Shen, Q; Speers, C; Steinbis, E; Wakeling, A; Xu, X; Zhang, Y	1
Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y	1
Kurebayashi, J; Okubo, S; Sonoo, H; Yamamoto, Y	1
Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z	1
Aulmann, S; Bastert, G; Koehler, M; Kolay, S; Schneeweiss, A; Torode, J; Von Minckwitz, G	1
Arteaga, CL; Truica, CI	1
Bally, MB; Chia, S; Denyssevych, T; Dragowska, WH; Gelmon, K; Masin, D; Wallis, AE; Warburton, C; Yan, H	1
Hayes, DF	1
Ali, S; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Wakeling, AE; Weiss, H	1
Barrow, D; Dutkowskil, C; Hiscox, S; Morgan, L; Nicholson, RI; Wakeling, A	1
Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF	1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P	1
Von Pawel, J	1
Aoe, M; Doihara, H; Hara, H; Ishibe, Y; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Teramoto, J; Yoshitomi, S	1
Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE	1
du Bois, A; Eiermann, W; Fasching, P; Hilfrich, J; Jonat, W; Kettner, E; Kleeberg, U; Lück, HJ; Schneeweiss, A; Torode, J; von Minckwitz, G	1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M	1
Apáti, A; Buday, L; Elkind, NB; Homolya, L; Kéri, G; Német, K; Ozvegy-Laczka, C; Sarkadi, B; Szabó, K; Szentpétery, Z; Ujhelly, O; Váradi, A; Várady, G	1
Kris, MG; Lobo, J; Rosen, N; Scher, HI; She, Y; Sirotnak, FM; Solit, DB	1
Yatabe, Y	1
Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG	1
Magné, N; Milano, G	1
Gasparini, G; Longo, R; Morabito, A; Torino, F	1
Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D	1
Albanell, J; Baselga, J; Gascón, P; González, S; Guillém, V; Koehler, MT; Lluch, A; Marimón, I; Rojo, F; Ruiz, A; Sauleda, S; Tabernero, JM	1
Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Kosmidis, P; Kourea, H; Lambropoulos, S; Linardou, H; Markopoulos, C; Mavroudis, D; Papadimitriou, C; Papadopoulos, S; Pavlidis, N; Pectasides, D; Razis, E; Skarlos, D	1
Camirand, A; Pollak, M; Young, F; Zakikhani, M	1
Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC	1
Amici, S; Gasparini, G; Gattuso, D; Gion, M; Longo, R; Sarmiento, R; Zancan, M	1
Agrawal, A; Gee, JM; Gutteridge, E; Nicholson, RI; Robertson, JF	1
Campiglio, M; De Luca, A; Menard, S; Normanno, N; Perrone, F	1
Eicke, N; Emons, G; Gründker, C; Günthert, AR; Läsche, J; Olota, A	1
Jazieh, AR; Nahleh, ZA	1
Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM	1
Barrow, D; Gee, J; Green, TP; Hiscox, S; Morgan, L; Nicholson, RI	1
Jacobson, JW; Lively, TG; Taube, SE	1
Campiglio, M; Carotenuto, A; De Luca, A; Maiello, MR; Mancino, M; Menard, S; Napolitano, M; Normanno, N; Viglietto, G	1
Schwartz, LM; Woloshin, S	1
Balsari, A; Campiglio, M; Castiglioni, F; Ménard, S; Pupa, SM; Tagliabue, E	1
Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA	1
Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T	1
Chan, SK; Gullick, WJ; Hill, ME	1
Carotenuto, A; Cito, L; D'Alessio, A; De Luca, A; Guzzo, A; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM	1
Chen, B; Cheng, D; Jordan, VC; Liu, H; Louis, TE; Osipo, C; Weichel, AK; Wing, LK	1
Doihara, H; Fujita, T; Ishibe, Y; Kawasaki, K; Ogasawara, Y; Shien, T; Taira, N; Takabatake, D; Takahashi, H; Yoshitomi, S	1
Carlini, P; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Milella, M; Nuzzo, C; Papaldo, P; Ruggeri, EM	1
Aglietta, M; Montemurro, F; Valabrega, G	1
Barrow, D; Burmi, RS; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI	1
Gaiger, A; Grunt, TW; Kainz, B; Köhler, G; Puckmair, K; Rünzler, D; Tomek, K; Wagner, R; Zielinski, CC	1
Bally, MB; Dragowska, WH; Edwards, L; Gelmon, K; Huxham, LA; Minchinton, AI; Ramsay, EC; Verreault, M; Warburton, C; Yapp, DT	1
Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM	1
Arpino, G; Bharwani, L; De Placido, S; Gutierrez, C; Massarweh, S; Osborne, CK; Rimawi, M; Schiff, R; Weiss, H	1
Aakre, ME; Arteaga, CL; Bonine-Summers, AR; Brown, KA; Cheng, N; Moses, HL; Pietenpol, JA	1
Han, WD; Hao, HJ; Li, Q; Li, XH; Si, YL; Wu, ZQ; Zhao, YL	1
Brunet, J; Colomer, R; De Llorens, R; Ferrer-Soler, L; Menendez, JA; Vazquez-Martin, A	1
Allan, G; Campbell, MJ; Goldfine, ID; Hodges, L; Kerner, JA; Kushner, P; Maddux, BA; Shiry, L; Youngren, JF; Zavodovskaya, M	1
Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N	1
Dibbley, SK; Lonardo, F; Piechocki, MP; Yoo, GH	2
Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G	1
Koike, A; Ohta, T	1
Barrow, D; Ellis, IO; Gee, JM; Hiscox, SE; Hutcheson, IR; Knowlden, JM; Nicholson, RI; Robertson, JF	1
Andreetta, C; Banna, G; Battelli, N; Berardi, R; Bisagni, G; Boni, C; Bottini, A; Conte, P; Cresti, N; Di Blasio, B; Ficarra, G; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Maiorana, A; Michelotti, A; Piacentini, F; Puglisi, F; Santoro, A	1
Eichler, GS; Kane, D; Reimers, M; Weinstein, JN	1
Aparicio, S; Astanehe, A; Buys, TP; Dunn, SE; Habibi, G; Hu, K; Jiang, H; Klinge, U; Lam, W; Marra, M; Mertens, PR; Nielsen, TO; Park, E; Pugh, T; Shadeo, A; Stratford, AL	1
Andersson, M; Nielsen, DL	1
Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI	1
Bajetto, A; Barbieri, F; Favoni, R; Ferrari, A; Florio, T; Gatti, M; Lunardi, G; Pattarozzi, A; Porcile, C; Ratto, A; Würth, R	1
Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F	1
Aliu, S; Hann, B; Hom, YK; Hylton, NM; Li, KL; Moasser, MM; Wang, D; Wilmes, LJ; Wong, CH	1
Chen, CS; Chen, Y; Choong, LY; Druker, BJ; Hande, MP; Lim, S; Lim, YP; Loh, MC; Man, X; Pan, M; Poonepalli, A; Salto-Tellez, M; Shah, N; Tan, PH; Toy, W; Wong, CY	1
Campiglio, M; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Mancino, M; Menard, S; Normanno, N	1
Albergaria, A; Coombes, RC; Francis, RE; Krol, J; Lam, EW; Polychronis, A; Sunters, A	1
Creighton, CJ; Huang, S; Massarweh, S; Osborne, CK; Qin, L; Rimawi, M; Schiff, R; Tsimelzon, A; Weiss, H	1
Arlt, D; Korf, U; Laible, M; Löbke, C; Poustka, A; Rappl, C; Ruschhaupt, M; Sahin, O; Sültmann, H; Wiemann, S	1
Hamburger, AW	1
Boerner, JL; Ethier, SP; Hunter, LA; Mueller, KL	1
Bundred, NJ; Chan, KC; Gandhi, A; Knox, WF; Potten, CS; Slamon, DJ	1
Barrow, D; Dutkowski, CM; Gee, JM; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Pamment, J	1
Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A	1
Averbuch, SD; Basso, A; Moasser, MM; Rosen, N	1
Fry, DW; Slichenmyer, WJ	1
Arteaga, CL; Bianco, R; Moulder, SL; Muthuswamy, SK; Simpson, JF; Yakes, FM	1
Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM; Zunino, F	1
Bundred, NJ; Chan, KC; Gee, JM; Knox, WF; Morris, J; Nicholson, RI; Potten, CS	1
Campiglio, M; Ciardiello, F; De, LA; Gianni, L; Maiello, M; Menard, S; Normanno, N; Salomon, DS; Somenzi, G	1
Baselga, J	1
Gee, JM; Nicholson, RI; Wakeling, AE	1
Bianco, AR; Biroccio, A; Borriello, G; Caputo, R; Ciardiello, F; Del Bufalo, D; Tortora, G; Zupi, G	1
Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI; Wakeling, AE	1

Reviews

42 review(s) available for gefitinib and Breast Neoplasms

Article	Year
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European journal of medicinal chemistry, 2022, Jul-05, Volume: 237 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells	2022
Glycosphingolipids in human embryonic stem cells and breast cancer stem cells, and potential cancer therapy strategies based on their structures and functions. Glycoconjugate journal, 2022, Volume: 39, Issue:2 Topics: Breast Neoplasms; ErbB Receptors; Female; Gangliosides; Gefitinib; Glycosphingolipids; Human Embryonic Stem Cells; Humans; MCF-7 Cells; Neoplastic Stem Cells	2022
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
The efficacy of gefitinib supplementation for breast cancer: A meta-analysis of randomized controlled studies. Medicine, 2020, Oct-23, Volume: 99, Issue:43 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Middle Aged; Randomized Controlled Trials as Topic	2020
Targeting receptor tyrosine kinases in HER2-negative breast cancer. Current opinion in oncology, 2013, Volume: 25, Issue:6 Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Nitriles; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Treatment Outcome; Triazoles; Up-Regulation	2013
Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles	2014
Emerging EGFR antagonists for breast cancer. Expert opinion on emerging drugs, 2014, Volume: 19, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cetuximab; Drug Discovery; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2014
Dual HER2 blockade: preclinical and clinical data. Breast cancer research : BCR, 2014, Aug-01, Volume: 16, Issue:4 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2014
[Companion Diagnostics for Solid Tumors]. Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:11 Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab	2015
[Living with incurable cancer]. Nederlands tijdschrift voor geneeskunde, 2016, Volume: 160 Topics: Aged; Anxiety; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Depression; Emotions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Psychotherapy; Quality of Life; Quinazolines	2016
Emerging treatment combinations: integrating therapy into clinical practice. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Dec-01, Volume: 66, Issue:23 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Everolimus; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Models, Biological; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2009
The molecular pathology of cancer. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:5 Topics: Adenocarcinoma; Base Sequence; Breast Neoplasms; Female; Gefitinib; Genes, ras; Genome-Wide Association Study; Humans; Male; Mutation; Neoplasms; Nervous System Neoplasms; Pathology, Molecular; Quinazolines; Signal Transduction	2010
[Oncology 2010]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:25-26 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome	2010
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wiener medizinische Wochenschrift (1946), 2010, Volume: 160, Issue:19-20 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphatidylinositol 3-Kinase; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2010
ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Medicinal research reviews, 2012, Volume: 32, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2012
Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies. Onkologie, 2002, Volume: 25, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Immunotoxins; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2002
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Receptor, ErbB-2; Trastuzumab	2002
ZD1839 (Iressa): for more than just non-small cell lung cancer. The oncologist, 2002, Volume: 7 Suppl 4 Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome	2002
The role of EGFR-directed therapy in the treatment of breast cancer. Breast cancer research and treatment, 2002, Volume: 75 Suppl 1 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mammary Neoplasms, Experimental; Quinazolines	2002
New directions for ZD1839 in the treatment of solid tumors. Seminars in oncology, 2003, Volume: 30, Issue:1 Suppl 1 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines	2003
The biology of antihormone failure in breast cancer. Breast cancer research and treatment, 2003, Volume: 80 Suppl 1 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction	2003
Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention? Journal of the National Cancer Institute, 2003, Dec-17, Volume: 95, Issue:24 Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Protein-Tyrosine Kinases; Quinazolines	2003
Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast cancer (Tokyo, Japan), 2004, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Gene Expression Regulation; Genes, erbB-1; Humans; Quinazolines; Signal Transduction	2004
Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. Seminars in oncology, 2004, Volume: 31, Issue:1 Suppl 3 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Quinazolines	2004
Targeted therapies for cancer 2004. American journal of clinical pathology, 2004, Volume: 122, Issue:4 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab	2004
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bulletin du cancer, 2004, May-01, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines	2004
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles	2005
[Molecular diagnosis of solid tumors]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Trastuzumab	2005
[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer]. Bulletin du cancer, 2004, Dec-01, Volume: 91 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estradiol; Taxoids; Trastuzumab	2004
Therapy of breast cancer with molecular targeting agents. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine	2005
Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocrine-related cancer, 2005, Volume: 12 Suppl 1 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2005
Cancer diagnostics: decision criteria for marker utilization in the clinic. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 2005, Volume: 5, Issue:6 Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab	2005
The role of the epidermal growth factor receptor in breast cancer. Journal of mammary gland biology and neoplasia, 2006, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2	2006
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab	2007
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-related cancer, 2006, Volume: 13 Suppl 1 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoproteins; Quinazolines; Signal Transduction	2006
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). International journal of molecular medicine, 2007, Volume: 20, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Models, Biological; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3	2007
[Predictive markers in breast cancer treatment--focusing on a recent topic "basal-like breast cancer"]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Anthracyclines; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Estrogen Receptor alpha; Female; Forecasting; Gefitinib; Gene Expression Profiling; Humans; Mutation; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Tubulin	2007
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors]. Ugeskrift for laeger, 2007, Sep-10, Volume: 169, Issue:37 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab	2007
[Targeting ErbB receptors in breast cancer]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2007
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. Journal of mammary gland biology and neoplasia, 2008, Volume: 13, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gefitinib; Humans; Membrane Glycoproteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; RNA-Binding Proteins; Tamoxifen; Ubiquitin-Protein Ligases	2008
Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 16 Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab	2001
Prospects for combining hormonal and nonhormonal growth factor inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Suppl Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen	2001

Trials

27 trial(s) available for gefitinib and Breast Neoplasms

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Microscopy, Fluorescence; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Quinazolines	2014
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast cancer research : BCR, 2014, Jun-30, Volume: 16, Issue:3 Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; TOR Serine-Threonine Kinases; Triazoles	2014
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378) European journal of cancer (Oxford, England : 1990), 2016, Volume: 53 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Early Termination of Clinical Trials; Female; Gefitinib; Humans; Middle Aged; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles	2016
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-01, Volume: 14, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome	2008
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast cancer research and treatment, 2009, Volume: 117, Issue:3 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Quinazolines	2009
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Receptors, Estrogen; Receptors, Progesterone	2009
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. International journal of cancer, 2010, Apr-15, Volume: 126, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen	2010
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-15, Volume: 16, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles	2010
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. International journal of clinical oncology, 2010, Volume: 15, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boston; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Gefitinib; Genital Neoplasms, Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome	2010
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Treatment Outcome	2011
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast cancer research and treatment, 2011, Volume: 126, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden	2011
Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast cancer research and treatment, 2011, Volume: 128, Issue:1 Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Phenotype; Quinazolines; Receptor, ErbB-2	2011
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast cancer research and treatment, 2011, Volume: 129, Issue:3 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles	2011
A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 131, Issue:3 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome	2012
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast cancer research and treatment, 2012, Volume: 133, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles	2012
A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clinical breast cancer, 2003, Volume: 4, Issue:2 Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Infusions, Intravenous; Neoplasm Metastasis; Quinazolines; Trastuzumab; Treatment Outcome	2003
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast cancer research and treatment, 2005, Volume: 89, Issue:2 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Survival Analysis; Taxoids; Treatment Outcome	2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. The Lancet. Oncology, 2005, Volume: 6, Issue:6 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; England; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography	2005
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-10, Volume: 23, Issue:23 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Neoplasms; Breast Neoplasms; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Salvage Therapy; Soft Tissue Neoplasms; Treatment Outcome; Tumor Suppressor Proteins	2005
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast cancer research and treatment, 2005, Volume: 92, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Gefitinib; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Treatment Outcome	2005
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; ErbB Receptors; Female; Gefitinib; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2	2005
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2). Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Gefitinib; Humans; Neoplasm Metastasis; Patient Selection; Quinazolines; Receptor, ErbB-2; Trastuzumab	2003
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. British journal of cancer, 2006, Jun-05, Volume: 94, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome	2006
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Investigational new drugs, 2007, Volume: 25, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome	2007
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Gefitinib; Humans; Ki-67 Antigen; Mastectomy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Triazoles	2007
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. Breast cancer research and treatment, 2008, Volume: 110, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Ki-67 Antigen; Neoplasm Staging; Paclitaxel; Patient Compliance; Quinazolines; Vascular Endothelial Growth Factor Receptor-1	2008

Other Studies

161 other study(ies) available for gefitinib and Breast Neoplasms

Article	Year
Design and synthesis of new stabilized combi-triazenes for targeting solid tumors expressing the epidermal growth factor receptor (EGFR) or its closest homologue HER2. Bioorganic & medicinal chemistry letters, 2009, Sep-15, Volume: 19, Issue:18 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Mice; Models, Molecular; NIH 3T3 Cells; Protein Binding; Receptor, ErbB-2; Triazenes	2009
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines. Bioorganic & medicinal chemistry letters, 2017, 02-01, Volume: 27, Issue:3 Topics: Amides; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Indoles; MCF-7 Cells; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Structure-Activity Relationship	2017
Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Mice, Inbred ICR; Mice, Nude; Molecular Docking Simulation; Rats; STAT3 Transcription Factor	2017
First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents. Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7 Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Neoplasms; NF-kappa B; Quinazolines; Signal Transduction; Thiourea	2017
2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K. European journal of medicinal chemistry, 2019, Jun-15, Volume: 172 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Molecular Docking Simulation; Molecular Structure; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship	2019
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Bioorganic & medicinal chemistry, 2020, 09-15, Volume: 28, Issue:18 Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles	2020
RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs). Genes, 2021, 10-23, Volume: 12, Issue:11 Topics: Alternative Splicing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Receptor Activator of Nuclear Factor-kappa B; Receptors, Estrogen	2021
Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. Journal of medicinal chemistry, 2022, 03-24, Volume: 65, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Tamoxifen; Triple Negative Breast Neoplasms	2022
Dual Drug Loaded Potassium-contained Graphene Oxide as a Nanocarrier in Cocktailed Drug Delivery for the Treatment of Human Breast Cancer. Current drug delivery, 2023, Volume: 20, Issue:7 Topics: Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Female; Gefitinib; Graphite; Humans; Pharmaceutical Preparations	2023
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers. International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19 Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen	2022
Assembly of nanostructured lipid carriers loaded gefitinib and simvastatin as hybrid therapy for metastatic breast cancer: Codelivery and repurposing approach. Drug development research, 2023, Volume: 84, Issue:7 Topics: Breast Neoplasms; Drug Carriers; Drug Repositioning; Female; Gefitinib; Humans; Lipids; Particle Size; Simvastatin	2023
Copper homeostasis-associated gene PRNP regulates ferroptosis and immune infiltration in breast cancer. PloS one, 2023, Volume: 18, Issue:8 Topics: Breast Neoplasms; Copper; Female; Ferroptosis; Gefitinib; Homeostasis; Humans; Prion Proteins; Prions; Reactive Oxygen Species	2023
Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers. Nanomedicine (London, England), 2023, Volume: 18, Issue:18 Topics: Breast Neoplasms; Drug Carriers; Female; Gefitinib; Humans; Lipids; Nanostructures; Particle Size	2023
Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β International journal of molecular sciences, 2020, Jul-13, Volume: 21, Issue:14 Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Collagen Type I; Discoidin Domain Receptor 1; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indazoles; Integrin beta1; Integrin beta4; MAP Kinase Signaling System; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Piperazines; Tumor Microenvironment	2020
Antioxidant functions of DHHC3 suppress anti-cancer drug activities. Cellular and molecular life sciences : CMLS, 2021, Volume: 78, Issue:5 Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference	2021
Mucin-1 conjugated polyamidoamine-based nanoparticles for image-guided delivery of gefitinib to breast cancer. International journal of biological macromolecules, 2021, Mar-31, Volume: 174 Topics: Breast Neoplasms; Cell Line, Tumor; Dendrimers; Drug Delivery Systems; Female; Gefitinib; Humans; MCF-7 Cells; Mucin-1; Nanoparticles; Polyamines; Polyethylene Glycols	2021
Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC cancer, 2021, Jun-01, Volume: 21, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carbazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; MAP Kinase Signaling System; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; rac GTP-Binding Proteins; Receptor, ErbB-2; Spheroids, Cellular; Up-Regulation	2021
Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype. Oncotarget, 2017, Jul-18, Volume: 8, Issue:29 Topics: Aldehyde Dehydrogenase 1 Family; Animals; Biomarkers; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Clonal Evolution; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycosphingolipids; Humans; Isoenzymes; Mice; Neoplastic Stem Cells; Phenotype; Quinazolines; Receptors, Growth Factor; Retinal Dehydrogenase; Sialyltransferases; Signal Transduction; Xenograft Model Antitumor Assays	2017
Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells. Chemical & pharmaceutical bulletin, 2017, Aug-01, Volume: 65, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cladribine; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship	2017
The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis. Cell death & disease, 2017, 07-13, Volume: 8, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred BALB C; MicroRNAs; Middle Aged; Nuclear Proteins; Protein Tyrosine Phosphatases; Quinazolines; Signal Transduction; Transplantation, Homologous	2017
Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. International journal of molecular sciences, 2017, 07-29, Volume: 18, Issue:8 Topics: Breast Neoplasms; Cell Communication; Cell Line, Tumor; Coculture Techniques; ErbB Receptors; Female; Gefitinib; Humans; Mesenchymal Stem Cells; Monocytes; Neoplasm Metastasis; Neoplasm Proteins; Osteoclasts; Quinazolines; Signal Transduction	2017
Akt1 inhibition promotes breast cancer metastasis through EGFR-mediated β-catenin nuclear accumulation. Cell communication and signaling : CCS, 2018, 11-16, Volume: 16, Issue:1 Topics: Active Transport, Cell Nucleus; beta Catenin; Breast Neoplasms; Cell Nucleus; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt	2018
GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy. Journal of experimental & clinical cancer research : CR, 2018, Nov-29, Volume: 37, Issue:1 Topics: Animals; Autophagy; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Female; Gefitinib; Humans; Lactic Acid; MCF-7 Cells; Mesylates; Mice, Inbred BALB C; Mice, Nude; Oxadiazoles; Receptors, G-Protein-Coupled; Tetrazoles; Thiazoles; Transfection	2018
Suppression of epidermal growth factor receptor-mediated β-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer. Cell biology international, 2019, Volume: 43, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Phosphoinositide-3 Kinase Inhibitors	2019
ASTEMIZOLE, AN INHIBITOR OF ETHER-À-GO-GO-1 POTASSIUM CHANNEL, INCREASES THE ACTIVITY OF THE TYROSINE KINASE INHIBITOR GEFITINIB IN BREAST CANCER CELLS. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 2019, Volume: 71, Issue:3 Topics: Antineoplastic Agents; Astemizole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Protein Kinase Inhibitors	2019
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. Journal of cellular and molecular medicine, 2013, Volume: 17, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Furans; Gefitinib; Humans; Inhibitory Concentration 50; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Quinazolines; Signal Transduction	2013
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PloS one, 2013, Volume: 8, Issue:10 Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Breast Neoplasms; Cadaverine; Cell Line, Tumor; Cell Survival; Cytoplasmic Vesicles; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Gene Silencing; Humans; Hydroxychloroquine; Membrane Proteins; Mice; Phagosomes; Quinazolines; RNA, Small Interfering; Signal Transduction; Staining and Labeling; Tamoxifen; Treatment Outcome; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays	2013
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin. International journal of oncology, 2014, Volume: 44, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines	2014
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast cancer research and treatment, 2014, Volume: 144, Issue:2 Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays	2014
Clinical trials: More trials, fewer tribulations. Nature, 2014, May-29, Volume: 509, Issue:7502 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size	2014
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors. BMC cancer, 2014, Dec-03, Volume: 14 Topics: Animals; Antigens, Surface; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Etoposide; Female; Gefitinib; Humans; Immunophenotyping; MCF-7 Cells; Mice; Neoplastic Stem Cells; Quinazolines; Spheroids, Cellular; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	2014
Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells. The Journal of steroid biochemistry and molecular biology, 2015, Volume: 148 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Breast Neoplasms; Calcitriol; Caspase 3; Cell Cycle; Cell Proliferation; Drug Synergism; Female; Gefitinib; Humans; Membrane Proteins; Proto-Oncogene Proteins; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vitamins	2015
[Effect of recombinant human p53 adenovirus (Ad-p53) combined with EGFR inhibitor gefitinib on the sensitivity of breast cancer MDA-MB-468 cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:12 Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 9; Cell Line, Tumor; Down-Regulation; Gefitinib; Genes, p53; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinazolines	2014
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression. Scientific reports, 2015, Feb-03, Volume: 5 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; RNA, Messenger; Signal Transduction; Tamoxifen; Up-Regulation	2015
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer. Journal of the Egyptian National Cancer Institute, 2015, Volume: 27, Issue:3 Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography	2015
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PloS one, 2015, Volume: 10, Issue:5 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Drug Resistance, Neoplasm; ErbB Receptors; Exome; Female; Gefitinib; Gene Expression; Humans; Mice; Mice, Nude; Models, Biological; Mutation; Phosphatidylinositol 3-Kinases; Plasmids; Protein Kinase Inhibitors; Quinazolines; Transfection; Xenograft Model Antitumor Assays	2015
t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells. PloS one, 2015, Volume: 10, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tyrphostins	2015
The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine. African health sciences, 2015, Volume: 15, Issue:2 Topics: Adult; Antineoplastic Agents; Area Under Curve; Arginine; Breast Neoplasms; Case-Control Studies; Female; Gefitinib; Humans; Mass Spectrometry; Metabolomics; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity	2015
Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance. Genetics and molecular research : GMR, 2015, May-29, Volume: 14, Issue:2 Topics: Breast Neoplasms; Cadherins; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2015
Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Oncology reports, 2015, Volume: 34, Issue:3 Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Quinolines; Receptor, ErbB-2; Tamoxifen	2015
[Targeted therapy for solid tumors in the elderly]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab	2015
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino acids, 2016, Volume: 48, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine	2016
Rapid assessment of drug resistance of cancer cells to gefitinib and carboplatin using optical imaging. Analytical biochemistry, 2016, 07-01, Volume: 504 Topics: Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gefitinib; Humans; Optical Imaging; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms	2016
Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling. Molecular cell, 2016, 05-05, Volume: 62, Issue:3 Topics: Acyltransferases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; HEK293 Cells; Humans; Lipoylation; Mass Spectrometry; Mice; Mutation; NIH 3T3 Cells; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proteolysis; Quinazolines; RNA Interference; Signal Transduction; Structure-Activity Relationship; Transfection	2016
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC cancer, 2016, 08-02, Volume: 16 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Animals; Breast Neoplasms; Chromones; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Mice; Middle Aged; Morpholines; Mutation; Phosphoric Monoester Hydrolases; Polyethylene Glycols; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tissue Array Analysis; Xenograft Model Antitumor Assays	2016
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature communications, 2016, 08-30, Volume: 7 Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; beta-Transducin Repeat-Containing Proteins; Breast; Breast Neoplasms; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; Glycogen Synthase Kinase 3 beta; Glycosylation; Humans; Immunologic Surveillance; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Phosphorylation; Programmed Cell Death 1 Receptor; Protein Stability; Quinazolines; T-Lymphocytes; Tumor Escape; Ubiquitination; Xenograft Model Antitumor Assays	2016
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer. Oncotarget, 2016, Sep-27, Volume: 7, Issue:39 Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases	2016
Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition. Cell cycle (Georgetown, Tex.), 2008, Sep-15, Volume: 7, Issue:18 Topics: Animals; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Enzyme Activation; Gefitinib; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Receptor, ErbB-3; Serum; Signal Transduction	2008
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer research, 2008, Sep-15, Volume: 68, Issue:18 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Ovariectomy; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Xenograft Model Antitumor Assays	2008
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. International journal of oncology, 2008, Volume: 33, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Cross-Linking Reagents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Suppressor Protein p53; Up-Regulation	2008
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Taxoids	2009
Cross-talk between Notch and EGFR signaling in human breast cancer cells. Cancer investigation, 2009, Volume: 27, Issue:5 Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cells, Cultured; ErbB Receptors; Female; Gefitinib; Humans; Kidney; Protein Kinase Inhibitors; Quinazolines; Receptor, Notch1; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction	2009
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular cancer therapeutics, 2009, Volume: 8, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell Death; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured	2009
microRNA-205 regulates HER3 in human breast cancer. Cancer research, 2009, Mar-15, Volume: 69, Issue:6 Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Gefitinib; Genes, Tumor Suppressor; Genetic Therapy; Humans; Lapatinib; MicroRNAs; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-3; Transfection	2009
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. Journal of magnetic resonance imaging : JMRI, 2009, Volume: 29, Issue:5 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Mice; Mice, Nude; Outcome Assessment, Health Care; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2009
Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer biology & therapy, 2009, Volume: 8, Issue:15 Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Caveolin 1; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Activation; Enzyme Induction; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction	2009
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes & development, 2009, Aug-15, Volume: 23, Issue:16 Topics: ADAM Proteins; ADAMTS1 Protein; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; Epidermal Growth Factor; Female; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Matrix Metalloproteinase 1; Mice; Mice, Nude; Osteoblasts; Osteoprotegerin; Protein Kinase Inhibitors; Quinazolines; RANK Ligand; Signal Transduction	2009
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, Nov-17, Volume: 106, Issue:46 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2009
A mechanistic study on gefitinib-induced apoptosis reveals a new link between EGFR and hTERT in breast cancers. Archives of pharmacal research, 2009, Volume: 32, Issue:10 Topics: Apoptosis; Breast Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Telomerase	2009
Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Archives of pharmacal research, 2009, Volume: 32, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; ErbB Receptors; Female; Gefitinib; Humans; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Telomerase	2009
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast cancer research and treatment, 2010, Volume: 123, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Retinoblastoma-Like Protein p130; RNA Interference; RNA, Messenger; Signal Transduction; Time Factors; Trastuzumab	2010
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors. Breast cancer research : BCR, 2009, Volume: 11 Suppl 3 Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical	2009
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer letters, 2010, Aug-01, Volume: 294, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Transposable Elements; ErbB Receptors; Female; Gefitinib; Genetic Variation; Glioblastoma; Humans; Mitochondria; Proto-Oncogene Proteins; Quinazolines; Sequence Deletion; Transplantation, Heterologous	2010
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lapatinib; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays	2011
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PloS one, 2010, Mar-16, Volume: 5, Issue:3 Topics: Adenylate Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Breast Neoplasms; Calcium; Cell Line, Tumor; Elongation Factor 2 Kinase; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lapatinib; Quinazolines; Signal Transduction; Trastuzumab	2010
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. Current cancer drug targets, 2010, Volume: 10, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib	2010
Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer research, 2010, Jul-01, Volume: 70, Issue:13 Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Benzodiazepinones; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dipeptides; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Notch; Signal Transduction; Xenograft Model Antitumor Assays	2010
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. Journal of cellular physiology, 2011, Volume: 226, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Trastuzumab	2011
IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. The Journal of biological chemistry, 2010, Dec-10, Volume: 285, Issue:50 Topics: Biotinylation; Breast; Breast Neoplasms; Cell Line, Tumor; Epidermal Growth Factor; Fibronectins; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Laminin; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Radioimmunoassay; rho-Associated Kinases	2010
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell, 2011, Jan-18, Volume: 19, Issue:1 Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays	2011
Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. The Journal of biological chemistry, 2011, Jun-10, Volume: 286, Issue:23 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines	2011
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. Journal of cellular physiology, 2011, Volume: 226, Issue:9 Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes	2011
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. International journal of cancer, 2012, Jul-01, Volume: 131, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2012
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. Breast cancer research and treatment, 2012, Volume: 133, Issue:1 Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase	2012
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline	2012
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cellular signalling, 2012, Volume: 24, Issue:1 Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation	2012
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC cancer, 2011, Oct-01, Volume: 11 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays	2011
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PloS one, 2011, Volume: 6, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cetuximab; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Lapatinib; Molecular Sequence Data; Neoplasm Metastasis; Quinazolines; Transcription, Genetic	2011
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles	2011
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. Cellular signalling, 2012, Volume: 24, Issue:9 Topics: Animals; Breast Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Mice; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tumor Cells, Cultured	2012
A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells. Experimental cell research, 2012, Oct-01, Volume: 318, Issue:16 Topics: Antineoplastic Agents; Breast Neoplasms; Catalase; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction	2012
[Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:2 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytoskeleton; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction	2012
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PloS one, 2012, Volume: 7, Issue:7 Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Growth Differentiation Factor 15; Humans; MCF-7 Cells; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins	2012
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. The Journal of clinical investigation, 2012, Volume: 122, Issue:9 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Quinazolines; RNA Interference; Signal Transduction; Tyrphostins; Xenograft Model Antitumor Assays	2012
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. International journal of oncology, 2012, Volume: 41, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases	2012
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutrition and cancer, 2012, Volume: 64, Issue:7 Topics: Adenylate Kinase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation; Humans; Mice; Mice, SCID; Polyphenols; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Vitis; Xenograft Model Antitumor Assays	2012
The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents. Oncogene, 2014, Jan-02, Volume: 33, Issue:1 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Doxorubicin; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines	2014
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? Journal of oncology practice, 2012, Volume: 8, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines	2012
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget, 2012, Volume: 3, Issue:12 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays	2012
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer science, 2013, Volume: 104, Issue:5 Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome	2013
BAD: a good therapeutic target? Breast cancer research : BCR, 2003, Volume: 5, Issue:1 Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Carrier Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured	2003
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Death; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotides; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 2003, Volume: 144, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Flavonoids; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured	2003
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Dimerization; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Fluorescein-5-isothiocyanate; Gefitinib; Humans; Ligands; Models, Biological; Neuregulin-1; Phosphorylation; Precipitin Tests; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Time Factors	2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology, 2003, Volume: 144, Issue:11 Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen	2003
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12 Topics: Breast Neoplasms; Chromones; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Tumor Cells, Cultured	2003
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. Journal of cellular physiology, 2004, Volume: 198, Issue:2 Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2	2004
Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer research, 2003, Nov-15, Volume: 63, Issue:22 Topics: Amphiregulin; Animals; Antigens, CD; Antigens, Neoplasm; Basigin; Breast Neoplasms; Cell Communication; Cell Line, Transformed; Coculture Techniques; DNA, Antisense; EGF Family of Proteins; Epithelial Cells; ErbB Receptors; Female; Fibroblasts; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Glycoproteins; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger	2003
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer research, 2003, Nov-15, Volume: 63, Issue:22 Topics: Animals; Antibiotics, Antineoplastic; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; COS Cells; Enzyme Activation; Enzyme Inhibitors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinones; Receptor, ErbB-2	2003
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. Journal of the National Cancer Institute, 2003, Dec-17, Volume: 95, Issue:24 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Transgenic; Microfilament Proteins; Mitogen-Activated Protein Kinases; Muscle Proteins; Phosphorylation; Precancerous Conditions; Quinazolines; Receptors, Estrogen; Signal Transduction	2003
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. British journal of cancer, 2004, Jan-12, Volume: 90, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Signal Transduction; Tumor Cells, Cultured	2004
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin	2004
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839). Anti-cancer drugs, 2004, Volume: 15, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lymph Nodes; Middle Aged; Quinazolines; Receptors, Growth Factor; Remission Induction; Skin Neoplasms; Trastuzumab	2004
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Apr-01, Volume: 10, Issue:7 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Hypoxia; Mammary Neoplasms, Animal; Mice; Mice, SCID; Neoplasm Transplantation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab	2004
Tamoxifen: Dr. Jekyll and Mr. Hyde? Journal of the National Cancer Institute, 2004, Jun-16, Volume: 96, Issue:12 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Trastuzumab	2004
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. Journal of the National Cancer Institute, 2004, Jun-16, Volume: 96, Issue:12 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estrogen Receptor Modulators; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transplantation, Heterologous; Up-Regulation	2004
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & experimental metastasis, 2004, Volume: 21, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Phenotype; Quinazolines; Tamoxifen	2004
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer, 2004, Nov-23, Volume: 4 Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms	2004
PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839). Breast cancer (Tokyo, Japan), 2004, Volume: 11, Issue:4 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Invasiveness; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Type C Phospholipases	2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer research, 2005, Feb-15, Volume: 65, Issue:4 Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan	2005
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer research, 2005, Mar-01, Volume: 65, Issue:5 Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Phosphorylation; Quinazolines; Tumor Cells, Cultured	2005
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-01, Volume: 11, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Gefitinib; Mice; Mice, Nude; Paclitaxel; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured	2005
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Molecular cancer therapeutics, 2005, Volume: 4, Issue:4 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Mutation; Neoplasm Transplantation; Neoplasms; Quinazolines; Rats; Rats, Nude; Scintillation Counting; Signal Transduction; Time Factors; Tissue Distribution	2005
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast cancer research : BCR, 2005, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Female; Gefitinib; Humans; Insulin-Like Growth Factor I; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2005
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer research, 2005, Aug-01, Volume: 65, Issue:15 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan	2005
Is the gefitinib plus trastuzumab combination feasible in breast cancer patients? Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Patient Selection; Quinazolines; Reproducibility of Results; Trastuzumab; Treatment Outcome	2005
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen. European journal of endocrinology, 2005, Volume: 153, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Phosphorylation; Quinazolines; Signal Transduction; Tamoxifen; Triptorelin Pamoate	2005
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays	2005
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocrine-related cancer, 2005, Volume: 12, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid	2005
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment, 2006, Volume: 97, Issue:3 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Focal Adhesion Kinase 1; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Paxillin; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; Tamoxifen	2006
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. Journal of cellular physiology, 2006, Volume: 207, Issue:2 Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flavonoids; Gefitinib; Humans; Inhibitory Concentration 50; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transfection	2006
What's the rush? The dissemination and adoption of preliminary research results. Journal of the National Cancer Institute, 2006, Mar-15, Volume: 98, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Congresses as Topic; Diffusion of Innovation; Evidence-Based Medicine; Female; Gefitinib; Humans; Information Dissemination; Lung Neoplasms; Multicenter Studies as Topic; Neoplasms; Practice Patterns, Physicians'; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United States	2006
Role of exon-16-deleted HER2 in breast carcinomas. Endocrine-related cancer, 2006, Volume: 13, Issue:1 Topics: 3T3 Cells; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Drug Tolerance; Emodin; Enzyme Inhibitors; ErbB Receptors; Exons; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kidney; Mice; Mice, Inbred BALB C; Mice, Nude; Polymerase Chain Reaction; Quinazolines; Receptor, ErbB-2; RNA Splicing; Trastuzumab	2006
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-01, Volume: 12, Issue:7 Pt 1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays	2006
AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast cancer research and treatment, 2007, Volume: 102, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Flow Cytometry; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines	2007
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. International journal of oncology, 2006, Volume: 29, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Quinazolines	2006
Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231). International journal of cancer, 2007, Jan-01, Volume: 120, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase; Gefitinib; Humans; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured	2007
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Dec-10, Volume: 24, Issue:35 Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gefitinib; Humans; Isoenzymes; Lymphatic Metastasis; Middle Aged; Nitriles; Quinazolines; Triazoles	2006
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. Journal of cellular physiology, 2007, Volume: 211, Issue:3 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Quinazolines; Receptors, Retinoic Acid; RNA Processing, Post-Transcriptional; Transcription, Genetic; Tyrphostins; Up-Regulation	2007
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast cancer research and treatment, 2007, Volume: 106, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Mice; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases	2007
Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer biology & therapy, 2006, Volume: 5, Issue:11 Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Primers; Epigenesis, Genetic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Organ Specificity; Quinazolines; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction	2006
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. Journal of the National Cancer Institute, 2007, May-02, Volume: 99, Issue:9 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Trastuzumab	2007
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer biology & therapy, 2007, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Mammary Glands, Human; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases	2007
[Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer]. Yi chuan = Hereditas, 2007, Volume: 29, Issue:5 Topics: Adult; Age Distribution; Aged; Base Sequence; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Quinazolines; Racial Groups; Sex Distribution	2007
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. Journal of cellular biochemistry, 2008, Feb-01, Volume: 103, Issue:2 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Masoprocol; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Tamoxifen	2008
Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer research, 2007, Jul-15, Volume: 67, Issue:14 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Mice; Mice, Inbred BALB C; Point Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3	2007
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast cancer research : BCR, 2007, Volume: 9, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neuregulin-1; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen; Trastuzumab	2007
The LeFE algorithm: embracing the complexity of gene expression in the interpretation of microarray data. Genome biology, 2007, Volume: 8, Issue:9 Topics: Algorithms; Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Computational Biology; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Pattern Recognition, Automated; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Smoking	2007
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast cancer research : BCR, 2007, Volume: 9, Issue:5 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Nucleic Acid Hybridization; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tissue Array Analysis; Y-Box-Binding Protein 1	2007
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast cancer research and treatment, 2008, Volume: 111, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction	2008
17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Molecular pharmacology, 2008, Volume: 73, Issue:1 Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; ErbB Receptors; Estradiol; Gefitinib; Humans; Quinazolines; Transcriptional Activation	2008
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of magnetic resonance imaging : JMRI, 2007, Volume: 26, Issue:6 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capillary Permeability; Contrast Media; Gadolinium DTPA; Gefitinib; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2007
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Molecular cancer therapeutics, 2007, Volume: 6, Issue:11 Topics: Animals; Asian People; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Mice; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Reproducibility of Results	2007
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast cancer research and treatment, 2008, Volume: 112, Issue:1 Topics: Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinase 1; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured	2008
Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. International journal of cancer, 2008, Apr-15, Volume: 122, Issue:8 Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Lobular; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Up-Regulation	2008
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Molecular cancer therapeutics, 2007, Volume: 6, Issue:12 Pt 1 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Forkhead Box Protein O3; Forkhead Transcription Factors; G1 Phase; Gefitinib; Gene Silencing; Humans; Immunohistochemistry; Quinazolines; Resting Phase, Cell Cycle; RNA, Small Interfering	2007
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer research, 2008, Feb-01, Volume: 68, Issue:3 Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transcription, Genetic; Xenograft Model Antitumor Assays	2008
Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling. Proteomics, 2008, Volume: 8, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glutathione Transferase; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Recombinant Fusion Proteins; Reference Standards; Signal Transduction; Trastuzumab; Tumor Cells, Cultured	2008
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer research, 2008, May-01, Volume: 68, Issue:9 Topics: Breast Neoplasms; Cell Proliferation; Drug Combinations; Enzyme Activation; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Indoles; Phosphorylation; Piperazines; Protein Array Analysis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Sulfonamides; Tumor Cells, Cultured	2008
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. The British journal of surgery, 2001, Volume: 88, Issue:3 Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Trastuzumab; Tumor Cells, Cultured	2001
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology, 2001, Volume: 142, Issue:7 Topics: Antineoplastic Agents; Breast Neoplasms; Cytological Techniques; Drug Resistance; Enzyme Inhibitors; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured	2001
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer research, 2001, Aug-01, Volume: 61, Issue:15 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured	2001
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer research, 2001, Oct-01, Volume: 61, Issue:19 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Cells, Cultured	2001
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer research, 2001, Dec-15, Volume: 61, Issue:24 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catalytic Domain; Cell Cycle; Cell Division; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligodeoxyribonucleotides, Antisense; Ovarian Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001
Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000. Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 16 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Prenylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2001
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer research, 2002, Jan-01, Volume: 62, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cell Division; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Precancerous Conditions; Quinazolines; Xenograft Model Antitumor Assays	2002
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured	2002
Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Quinazolines; Receptor, ErbB-2; Trastuzumab	2002
ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. International journal of cancer, 2002, Mar-20, Volume: 98, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Taxoids; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured	2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Annals of the New York Academy of Sciences, 2002, Volume: 963 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endocrine Glands; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Trastuzumab; Tumor Cells, Cultured	2002